early insertion
ApprovedSmall molecule
early insertion is one of 36 small molecule programs targeting Vogt-Koyanagi-Harada disease. It is currently in Approved.
2
Indications
2
Total Trials
0
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
364 competitors in Growth
#DrugCompanyPhaseTrials
1early insertion
UUniversity of Sao Paulo
Approved
Genotropin
EMD SeronoPreclinical
Aricept
EisaiPreclinical
Zolymbus
AbbViePreclinical
Somavaratan
Novo NordiskPreclinical
Herceptin
OOrganon and Co
Preclinical
Glucophage
EMD SeronoPreclinical
EGRIFTA WR
TTheratechnologies
Preclinical
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
Prilosec
DDexcel Pharma Technologies Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for early insertion. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Sao Paulo